BioSpace6m
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
BioSpace20h
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...
BioSpace22h
BMS Adds $2B to Cost Cutting Plans, Eyes Deals After Cobenfy Success
Bristol Myers Squibb will make even deeper cuts to its organization to enhance efficiencies as it faces the 2028 loss of ...
BioSpace21h
BMS’ Cobenfy Sales Begin, With Launch Full Speed Ahead
Bristol Myers Squibb clocked $10 million in sales for new schizophrenia drug Cobenfy in the fourth quarter of 2024, with the ...
BioSpace22h
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...
BioSpace23h
AstraZeneca Axes Two Alexion Assets as Q4 Earnings Exceed Expectations
Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...